EP4698178A2 - Behandlung von nichtkleinzelligem lungenkrebs - Google Patents

Behandlung von nichtkleinzelligem lungenkrebs

Info

Publication number
EP4698178A2
EP4698178A2 EP24793476.3A EP24793476A EP4698178A2 EP 4698178 A2 EP4698178 A2 EP 4698178A2 EP 24793476 A EP24793476 A EP 24793476A EP 4698178 A2 EP4698178 A2 EP 4698178A2
Authority
EP
European Patent Office
Prior art keywords
osimertinib
pharmaceutically acceptable
acceptable salt
patient
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24793476.3A
Other languages
English (en)
French (fr)
Inventor
Matthew Meyerson
Lior GOLOMB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP4698178A2 publication Critical patent/EP4698178A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24793476.3A 2023-04-21 2024-04-18 Behandlung von nichtkleinzelligem lungenkrebs Pending EP4698178A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363497627P 2023-04-21 2023-04-21
PCT/US2024/025187 WO2024220666A2 (en) 2023-04-21 2024-04-18 Treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
EP4698178A2 true EP4698178A2 (de) 2026-02-25

Family

ID=93153533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24793476.3A Pending EP4698178A2 (de) 2023-04-21 2024-04-18 Behandlung von nichtkleinzelligem lungenkrebs

Country Status (2)

Country Link
EP (1) EP4698178A2 (de)
WO (1) WO2024220666A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210382037A1 (en) * 2017-07-10 2021-12-09 Dana-Farber Cancer Institute, Inc. Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents

Also Published As

Publication number Publication date
WO2024220666A3 (en) 2025-02-06
WO2024220666A2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
US12036227B2 (en) Combination therapy
US11759444B2 (en) Methods for cancer and immunotherapy using prodrugs of glutamine analogs
US20060270665A1 (en) Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
US8637493B2 (en) Methods for treating glioblastoma
ES2741399T3 (es) Apilimod para el uso en el tratamiento de cáncer renal
US20210154198A1 (en) Combination therapy involving diaryl macrocyclic compounds
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
US9795595B2 (en) Methods for treating cancer
WO2008023362A2 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2022228323A1 (zh) Ly3009120在制备治疗骨髓增殖性肿瘤的药物中的应用
TW202313039A (zh) Pm14用途與方案
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
HUE028025T2 (en) Use of Panobinostat HDAC inhibitor to treat myeloma
EP4203963B1 (de) Kombinationstherapie mit naporafenib und trametinib zur verwendung bei der behandlung von sarkom
WO2024220666A2 (en) Treatment of non-small cell lung cancer
EP3815709A1 (de) Pharmazeutische zusammensetzungen und verwendung davon zur abschwächung der resistenz gegen antikrebswirkstoff und zur erhöhung der empfindlichkeit gegen antikrebswirkstoff
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
TW202114682A (zh) Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
US12226454B2 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
US20220304985A1 (en) Combination therapy for proliferative conditions
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR